Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00389363|
Recruitment Status : Completed
First Posted : October 18, 2006
Last Update Posted : August 17, 2010
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: ALK HDM tablet||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||800 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients|
|Study Start Date :||August 2006|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||April 2008|
- Use of inhaled corticosteroid (ICS).
- Use of rescue medication and symptoms.
- Quality of Life.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00389363
|Copenhagen, Denmark, 2100|
|Study Director:||Kim Simonsen, MD.||ALK-Abelló|